[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598610":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":46,"locations":52,"responsibleParty":66,"collaborators":50,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":50,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":50,"enrollmentInfo":77,"targetDuration":50,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":89,"whyStopped":50,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Corneal Neurotization","EXPERIMENTAL","Participants in this arm will receive corneal neurotization surgery as part of their standard clinical care. The surgical procedure involves transferring healthy donor nerves to the anesthetic cornea in order to restore corneal sensation. Participants are followed over 12 months without randomization.",[13],"Procedure: Corneal Neurotization",{"label":15,"type":16,"description":17,"interventionNames":18},"Cenergermin","ACTIVE_COMPARATOR","Participants in this arm will receive topical Cenergermin (Oxervate) eye drops, a recombinant human nerve growth factor approved for treatment of neurotrophic keratitis. Treatment is selected based on clinical decision-making. Participants are followed over 12 months as part of routine care.",[19],"Drug: Cenergermin",[21,28],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","Surgical technique involving the transfer of healthy donor sensory nerves to the anesthetic cornea to restore corneal innervation and sensation in patients with neurotrophic keratitis.",[9],[26,27],"Corneal Nerve Transfer","Corneal Sensory Nerve Grafting",{"type":29,"name":15,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","Topical recombinant human nerve growth factor (rhNGF) approved for the treatment of neurotrophic keratitis. Administered as eye drops, it promotes epithelial healing and nerve regeneration.",[15],[33],"Oxervate",[35,39,42,44],{"name":36,"affiliation":37,"role":38},"Alex Camacho, MD, MSc","Western University, Ophthalmology","PRINCIPAL_INVESTIGATOR",{"name":40,"affiliation":37,"role":41},"Cindy Hutnik, MD, PhD, Department Chief","STUDY_CHAIR",{"name":43,"affiliation":37,"role":41},"Monali Malvankar, PhD, Professor",{"name":45,"affiliation":37,"role":41},"Anastasiya Vinokurtseva, MD, Resident",[47],{"name":36,"role":48,"phone":49,"phoneExt":50,"email":51},"CONTACT","519-646-6100",null,"Alex.camacho@sjhc.london.on.ca",[53],{"facility":54,"status":50,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":50},"Ivey Eye Institute, St. Joseph's Health Care London","London","Ontario","N6A 4V2","Canada","CA",{"type":61,"coordinates":62},"Point",[63,64],-81.23304,42.98339,{"lat":64,"lon":63},{"type":67,"investigatorFullName":50,"investigatorTitle":50,"investigatorAffiliation":50,"oldNameTitle":50,"oldOrganization":50},"SPONSOR","100598610","corneal-neurotization-vs-cenergermin-for-neurotrophic-keratitis-a-pilot-study-100598610",false,"NCT07073729","Corneal Neurotization vs. Cenergermin for Neurotrophic Keratitis: A Pilot Study","Corneal Neurotization: A Study on the Outcomes of Nerve Repair for Corneal Sensory Dysfunction","Inclusion Criteria:\n\n* Adults aged 19 years and older.\n* Diagnosis of neurotrophic keratitis with reduced or absent corneal sensation.\n* Clinical indication for either corneal neurotization surgery or topical Cenergermin treatment, as determined by the treating ophthalmologist.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Active ocular infection or inflammation.\n* Previous corneal neurotization procedure in the affected eye.\n* Contraindications to general anesthesia or surgical intervention.\n* Participation in another interventional clinical trial within the past 3 months.","ALL","19 Years",{"count":78,"type":79},10,"ESTIMATED","INTERVENTIONAL",[82],"NA","This pilot study evaluates the feasibility and outcomes of two treatment approaches for corneal sensory dysfunction due to neurotrophic keratitis (NK): corneal neurotization surgery and topical Cenergermin (Oxervate). Participants will receive treatment based on clinical decision-making, not randomization, and will be followed for 12 months through eight visits at the Ivey Eye Institute, St. Joseph's Health Care London. Data collected during routine eye examinations and validated quality-of-life questionnaires will be used to assess visual outcomes, corneal structure and function, and patient-reported well-being. This feasibility study is funded by the Lawson Research Institute Internal Research Fund and is intended to generate preliminary evidence for a future randomized trial.",[85],"Neurotrophic Keratitis",[9,15,87,88],"Neurotrophic Keratopathy","Corneal Sensory Dysfunction","NOT_YET_RECRUITING","2025-07-09",{"date":92,"type":93},"2025-07-18","ACTUAL",{"date":95,"type":79},"2025-08-01",{"date":97,"type":79},"2027-08-01",{"name":5,"class":6},1]